Article Information
History
- May 18, 2021.
Article Versions
- Version 1 (May 9, 2021 - 19:31).
- You are currently viewing Version 2 of this article (May 18, 2021 - 06:31).
- Version 3 (June 28, 2021 - 13:49).
- Version 4 (July 16, 2021 - 11:19).
- View Version 5, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Isabella Ferreira1,2,*,
- Rawlings Datir1,2,*,
- Steven Kemp1,2,*,
- Guido Papa3,*,
- Partha Rakshit4,*,
- Sujeet Singh4,
- Bo Meng1,2,
- Rajesh Pandey5,
- Kalaiarasan Ponnusamy4,
- V.S. Radhakrishnan4,
- The Indian SARS-CoV-2 Genomics Consortium (INSACOG),
- The CITIID-NIHR BioResource COVID-19 Collaboration,
- Kei Sato7,
- Leo James3,*,
- Anurag Agrawal5,* and
- Ravindra K. Gupta1,2,*,#
- 1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
- 2Department of Medicine, University of Cambridge, Cambridge, UK
- 3MRC – Laboratory of Molecular Biology, Cambridge, UK
- 4National Centre for Disease Control, Delhi, India
- 5CSIR Institute of Genomics and Integrative Biology, Delhi, India
- 6Institute of Medical Science, University of Tokyo, Japan
- 7Africa Health Research Institute, Durban, South Africa
- ↵#Address for correspondence: Ravindra K. Gupta, Cambridge Institute for Therapeutic Immunology and Infectious Diseases, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge CB2 0AW, UK, Tel: +44 1223 331491, rkg20{at}cam.ac.uk
↵* Authors contributed equally to this work